Evaluation of CellThRPE1 in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

The primary objective of the study is to evaluate the efficacy and safety of the investigational treatment for **geographic atrophy** secondary to dry age-related macular degeneration. This condition is a progressive retinal disease that leads to vision loss, and assessing the treatment's impact is crucial for developing effective therapeutic strategies. The study aims to determine whether the treatment can slow the progression of geographic atrophy and improve visual outcomes for patients. No secondary objectives are provided in the available data.

The clinical trial focuses on participants diagnosed with **geographic atrophy secondary to dry age-related macular degeneration**. The study population includes both male and female subjects, with an age range spanning from 18 to 64 years. Participants are generally in good health, excluding the specified condition. The trial does not involve a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria for the trial population are not detailed, and no specific lifestyle considerations such as diet or physical activity are mentioned. Key inclusion or exclusion criteria have not been disclosed by the sponsor.

The clinical trial is designed to evaluate the safety and efficacy of an investigational treatment for **geographic atrophy secondary to dry age-related macular degeneration**. This study is structured as a Phase 1 trial, which typically focuses on assessing the safety profile of the investigational product. The trial is expected to commence recruitment on May 2, 2025, and is projected to conclude by August 2, 2032. The trial will employ a randomized, double-blind, controlled design to ensure the reliability and validity of the results.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to determine eligibility based on predefined criteria. Following successful screening, participants will be randomized into either the treatment or control group. The sequence of study visits will include regular follow-up assessments to monitor safety and efficacy outcomes. These visits are crucial for collecting data on the primary and secondary endpoints, although specific endpoints are not detailed in the available data. The end-of-study visit will mark the completion of the participant's involvement, where final assessments will be conducted to evaluate the long-term effects of the treatment.

The expected duration of participant involvement will vary depending on individual response and adherence to the study protocol. Participants may be subject to early termination from the study if they experience adverse events that compromise their safety, fail to comply with study procedures, or withdraw consent. The trial's design and procedures are meticulously planned to ensure the collection of high-quality data while prioritizing participant safety and well-being throughout the study duration.

No specific information regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration, is provided in the available data. Consequently, a detailed description of the experimental treatment cannot be formulated based on the current dataset.

Similarly, there is no information available about any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, used in the study. Therefore, a description of these elements is not possible with the given data.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also absent from the provided data. As such, no further details can be included in this description.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The trial is scheduled to commence recruitment on May 2, 2025, with an estimated completion date of August 2, 2032. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 1 trials typically focus on safety and dosage, with preliminary efficacy data being collected. The trial will likely employ standard methods for data collection and analysis, consistent with Phase 1 objectives, to ensure the reliability and validity of the findings. The absence of detailed endpoints suggests that the trial may utilize exploratory measures to assess efficacy, potentially including **biomarker** levels or other relevant clinical indicators. The trial's design will adhere to regulatory standards to ensure the integrity of the data collected throughout the study period.